Compare Abeona Therapeutics Inc (ABEO) vs AXT Inc (AXTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AXT Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while AXT Inc trades at $60.82 (market cap $3.80B). The key difference: AXT Inc is far larger — about 10.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, AXT Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | AXTI | |
|---|---|---|
Market Cap | $373.32M | $3.80B |
Sector | Health | Technology |
52-Week High | $7.23 | $140.83 |
52-Week Low | $4.17 | $1.92 |
Enterprise Value | $228.22M | $3.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AXTI trades at $63.52, up 12.19% today, but remains in a bearish technical trend with support at $60 and resistance at $64. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improving margins. Recent news highlights strong AI-driven demand for indium phosphide and a record $100M backlog, with earnings scheduled for July 30, 2026.
Outlook is mixed: analyst consensus is bullish (64% buy ratings) based on AI growth potential, but profitability challenges and geopolitical risks in China pose significant headwinds. The stock's high P/S ratio of 30.7 suggests premium valuation despite current losses, making execution critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →
